What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
The aborted trial of semagacestat has led some to invoke unanticipated effects of γ-secretase inhibition on formation of amyloid β. However, the many substrates for γ-secretases and the varied biological effects of each of the resultant cleavage products make ascribing causality much more complex than that.